Title: TIP60 Inhibitor TH1834 Reduces Breast Cancer Progression in Xenografts in Mice
Abstract: OMICS: A Journal of Integrative BiologyVol. 23, No. 9 Letter to the EditorTIP60 Inhibitor TH1834 Reduces Breast Cancer Progression in Xenografts in MiceMouhamed Idrissou, Gaëlle Judes, Marine Daures, Anna Sanchez, Driss El Ouardi, Sophie Besse, Françoise Degoul, Frédérique Penault-Llorca, Yves-Jean Bignon, and Dominique Bernard-GallonMouhamed IdrissouDepartment of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.INSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, Gaëlle JudesDepartment of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.INSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, Marine DauresDepartment of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.INSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, Anna SanchezDepartment of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.INSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, Driss El OuardiDepartment of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.INSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, Sophie BesseINSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, Françoise DegoulINSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, Frédérique Penault-LlorcaINSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France.Search for more papers by this author, Yves-Jean BignonDepartment of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.INSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this author, and Dominique Bernard-GallonAddress correspondence to: Dominique Bernard-Gallon, PhD, Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri Dunant, Clermont-Ferrand 63001, France E-mail Address: [email protected] of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.INSERM—UMR 1240—Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France.Search for more papers by this authorPublished Online:30 Aug 2019https://doi.org/10.1089/omi.2019.0126AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byThe role of protein acetylation in carcinogenesis and targeted drug discovery12 September 2022 | Frontiers in Endocrinology, Vol. 13The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell LymphomaAnti-Cancer Agents in Medicinal Chemistry, Vol. 22, No. 8Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer23 March 2022 | Biomedicines, Vol. 10, No. 4Digging Deeper into Breast Cancer Epigenetics: Insights from Chemical Inhibition of Histone Acetyltransferase TIP60 In Vitro Mouhamed Idrissou, Andre Lebert, Tiphanie Boisnier, Anna Sanchez, Fatma Zohra Houfaf Khoufaf, Frédérique Penault-Llorca, Yves-Jean Bignon, and Dominique Bernard-Gallon5 October 2020 | OMICS: A Journal of Integrative Biology, Vol. 24, No. 10Isoform- and Cell Type–Specific Roles of Glycogen Synthase Kinase 3 N-Terminal Serine Phosphorylation in Liver Ischemia Reperfusion Injury15 August 2020 | The Journal of Immunology, Vol. 205, No. 4Epi-drugs as triple-negative breast cancer treatmentEpigenomics, Vol. 12, No. 8Modulating Epigenetic Modification Enzymes Through Relevant Epidrugs as a Timely Strategy in Anticancer Therapy24 November 2020Patent spotlight: small-molecule lysine acetyltransferase inhibitors (KATi)Pharmaceutical Patent Analyst, Vol. 9, No. 1 Volume 23Issue 9Sep 2019 InformationCopyright 2019, Mary Ann Liebert, Inc., publishersTo cite this article:Mouhamed Idrissou, Gaëlle Judes, Marine Daures, Anna Sanchez, Driss El Ouardi, Sophie Besse, Françoise Degoul, Frédérique Penault-Llorca, Yves-Jean Bignon, and Dominique Bernard-Gallon.TIP60 Inhibitor TH1834 Reduces Breast Cancer Progression in Xenografts in Mice.OMICS: A Journal of Integrative Biology.Sep 2019.457-459.http://doi.org/10.1089/omi.2019.0126Published in Volume: 23 Issue 9: August 30, 2019Keywordsbreast cancerdrug targets and developmentTIP60TH1834xenograftsin vivo animal researchPDF download
Publication Year: 2019
Publication Date: 2019-09-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 15
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot